We seek transparency and dialogue with all stakeholders to improve our understanding of their needs. These stakeholders include patient associations, healthcare providers, shareholders, employees, authorities, the environment and local communities. We consult and engage with all our stakeholders on a regular basis and incorporate their feedback into the company’s strategy and risk management.
Patients and Patient Organizations
We engage with patient organizations and healthcare providers to better understand patients and their caregiver’s needs. This includes working with, and supporting, patient groups, as well as discussing with healthcare professionals the broader range of disease challenges they and their patients face. Our ongoing aim is to ensure that all of our relationships with patient groups and other healthcare organizations continue to be based on transparency, trust and a shared objective to improve the lives of patients.
Our day-to-day business activities include regular contact with physicians and other healthcare professionals. Our communications focuses on providing information about our medicines, the diseases they treat and the benefits and risks associated with their use.
In 2017, Idorsia's payments to Healthcare Professionals or Healthcare Organisations in Switzerland amounted to CHF 145,690.
Idorsia regularly offers the availability of Investor Relations personnel and senior management to the company’s capital market stakeholders. This includes presenting the company’s progress and opportunities for future growth at healthcare conferences, and visiting its clients to offer a better understanding of the company, its performance and its growth potential.
Where possible Idorsia also welcomes institutional investors and sell-side analysts to its headquarters to experience the company's culture and view the established drug discovery capabilities.
Idorsia also holds an Annual General Meeting of shareholders as an opportunity for the Board of Directors to report to the company’s shareholders on the progress made in the previous 12 months.
Idorsia can only achieve its ambitious goal to develop Idorsia into Europe’s leading biopharmaceutical company if we have an engaged workforce, with a clear sense of purpose and confidence in their abilities. To achieve this we recognize the need to provide effective leadership, clear targets, open lines of communication, learning and development opportunities and a safe workplace.
In addition to employee briefings, we use a wide range of electronic media to communicate regularly with our employees. Feedback opportunities are integrated into our internal communication programs and, in addition, our Code of Conduct outlines the procedures for employees to raise any potential concerns that he or she may have.